Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027947 (
neutropenia
)
17,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Breast cancer is the most common cancer in women worldwide. Doxorubicin-based chemotherapy is used to treat breast cancer patients; however,
neutropenia
is a common hematologic side effect and can be life-threatening. The ABCB1 and
SLC22A16
genes encode proteins that are essential for doxorubicin transport. In this study, we explored the effect of 2 common polymorphisms in ABCB1 (rs10276036 C/T) and
SLC22A16
(rs12210538 A/G) on the development of grade 3/4 febrile
neutropenia
in Iranian breast cancer patients. Our results showed no significant association between these polymorphisms and grade 3/4 febrile
neutropenia
; however, allele C of ABCB1 (rs10276036 C/T) (p = 0.315, OR = 1.500, 95% CI = 0.679-3.312) and allele A of
SLC22A16
(rs12210538 A/G) (p = 0.110, OR = 2.984, 95% CI = 0.743-11.988) tended to have a greater association with grade 3/4 febrile
neutropenia
, whereas allele T of ABCB1 (rs10276036) (p = 0.130, OR = 0.515, 95% CI = 0.217-1.223) and allele G of
SLC22A16
(rs12210538) (p = 0.548, OR = 0.786, 95% CI = 0.358-1.726) tended to protect against this condition. In addition to breast cancer, a statistically significant association was also observed between the development of grade 3/4 febrile
neutropenia
and other clinical manifestations such as stage IIIC cancer (p = 0.037) and other diseases (p = 0.026). Our results indicate that evaluation of the risk of grade 3/4
neutropenia
development and consideration of molecular and clinical findings may be of value when screening for high-risk breast cancer patients.
...
PMID:Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. 2803 87
Anthracycline uptake could be affected by influx and efflux transporters in acute myeloid leukemia (AML). Combinations of single-nucleotide polymorphisms (SNPs) of wild-type genotype of influx transporters (
SLC22A16
, SLCO1B1
) and homozygous variant genotypes of
ABC
polymorphisms (
ABCB1, ABCC1
,
ABCC2
,
ABCG2
) were evaluated in 225 adult
de novo
AML patients. No differences in complete remission were reported, but higher induction death was observed with combinations of
SLCO1B1
rs4149056 and
ABCB1
(triple variant haplotype, rs1128503), previously associated with
ABCB1
and
SLCO1B1
SNPs. Several combinations of
SLCO1B1
and
SLC22A16
with
ABCB1
SNPs were associated with higher toxicities, including nephrotoxicity and hepatotoxicity,
neutropenia
, previously related to
ABCB1
, and a novel correlation with mucositis. Combination of
SLC22A16
rs714368 and
ABCG2
rs2231142 was related to cardiac toxicity, reproducing previous correlations with
ABCG2
. This study shows the impact of transporter polymorphisms in AML chemotherapy safety. Further prospective studies with larger populations are needed to validate these associations.
...
PMID:Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. 3313 28